TY - JOUR AU - Puigdomenech Puig, Elisa AU - Robles, Noemí AU - Saigí-Rubió， Francesc AU - Zamora, Alberto AU - Moharra, Montse AU - Paluzie, Guillermo AU - Balfegó， Mariona AU - Cuatrecasas Cambra, Guillem AU - Garcia-Lorda, Pilar AU - Carrion, Carme PY - 2019 DA - 2019/10/25 TI -体重控制和肥胖管理的有效性、安全性和有效性评估:系统评价JO - JMIR Mhealth Uhealth SP - e12612 VL - 7 IS - 10 KW - Mhealth KW -肥胖KW -超重KW -系统评价KW -技术评估AB -背景:通过跟踪身体和饮食模式，并提供建议和激励策略来解决超重和肥胖问题，以实现个性化目标的应用程序近年来有所增加。然而，这些应用程序的功效、有效性和安全性的证据严重缺乏。目的:本研究的目的是通过系统回顾，确定用于评估移动健康(mHealth)干预措施中体重控制、超重和肥胖管理的有效性、安全性和有效性标准。方法:对PubMed、PsycINFO、Scopus、英国试验数据库、ClinicalTrials.gov和Cochrane图书馆进行调查，直至2018年5月。我们考虑了所有类型的临床研究。共有2名独立评审员使用苏格兰校际指南网络(SIGN)标准评估质量。评分用于提供每项研究的总体得分(低、中、高)。数据综合在证据表中。结果:在233篇潜在相关的出版物中，只有28篇研究被纳入。 Of these, 13 (46%) were randomized control trials, 11 were single-arm studies (39%), 3 were nonrandomized controlled trials (11%), and 1 study was a cluster randomized trial (4%). The studies were classified as low (15), high (7), and moderate (6) quality according to SIGN criteria. All studies focused on efficacy, with only 1 trial mentioning safety and another 1 effectiveness. In 11 studies, the apps were used as stand-alone interventions, the others were multicomponent studies that included other tools for support such as sensors or websites. The main management tool included in the apps was feedback messaging (24), followed by goal-setting mechanisms (20) and self-monitoring (19). The majority of studies took weight or body mass index loss as the main outcome (22) followed by changes in physical activity (14) and diet (12). Regarding outputs, usability, adherence, and engagement (17) were the most reported, followed by satisfaction (7) and acceptability (4). Conclusions: There is a remarkable heterogeneity among these studies and the majority have methodological limitations that leave considerable room for improvement. Further research is required to identify all relevant criteria for assessing the efficacy of mHealth interventions in the management of overweight and obesity. Trial Registration: PROSPERO CRD42017056761; https://tinyurl.com/y2zhxtjx SN - 2291-5222 UR - http://mhealth.www.mybigtv.com/2019/10/e12612/ UR - https://doi.org/10.2196/12612 UR - http://www.ncbi.nlm.nih.gov/pubmed/31654566 DO - 10.2196/12612 ID - info:doi/10.2196/12612 ER -